Document is current
Any future updates will be listed below
-
Authors
Viola, Luiz F. https://orcid.org/0000-0003-1167-7933
Campinos, Catherine
Trujilho, Fabio https://orcid.org/0009-0000-1987-8348
Valerio, Cynthia M. https://orcid.org/0000-0003-2292-1735
- License Information
-
More Information
Article History
Received: 16 April 2026
Accepted: 11 June 2026
First Online: 8 August 2026
Declarations
Competing interests: LFV declares that there are no relationships or activities that might bias, or be perceived to bias, his work. CC has received consulting fees from Eli Lilly, Novo Nordisk, AstraZeneca, Menarini and Sanofi. FRT reports consulting fees from Boston Scientific and Myralis; educational material development for Aché, Eurofarma, EMS and Myralis; preceptorship roles for ASCEND/EASO and Merck; and speaking fees from Aché, AstraZeneca, BracePharma, Boehringer Ingelheim, Eli Lilly, EMS, Eurofarma, Johnson & Johnson, Myrallis, Merck, Novo Nordisk, Servier, Scitech Medical and Takeda; he has received travel support from AstraZeneca, Chiesi, Merck, Eli Lilly, EMS, Eurofarma, Myralis, Novo Nordisk, Scitech Medical and Boston Scientific, and served on advisory boards for Boston Scientific, Novo Nordisk, Myralis, Eli Lilly and Merck; and he holds unpaid leadership roles within the World Obesity Federation, ABESO and FLASO. CMV reports a research contract with Chiesi; consulting fees from Eli Lilly, Novo Nordisk, Chiesi and Boehringer Ingelheim; speaking fees from Eli Lilly, Novo Nordisk, Chiesi, Merck, Abbvie, Boehringer-Ingelheim and EMS; travel support from Astra-Zeneca, Lilly, Novo Nordisk, Chiesi, Merck and EMS; participation on advisory boards for Chiesi and Lilly; and she holds an unpaid leadership role within ABESO.
